Roche Partners with Ascidian in $1.8 Billion RNA Exon Editing Deal for Neurological Diseases

1. Deal Value: The partnership between Roche and Ascidian is worth up to $1.8 billion.
2. Initial Payment: Roche will make an initial payment of $42 million to Ascidian.
3. Focus: The collaboration aims to develop RNA exon editing therapeutics for neurological diseases.
4. Partnership Terms: Ascidian is eligible for up to $1.8 billion in additional payments based on the deal's terms.
5. Neurological Diseases: The partnership targets the development of RNA exon editing therapies for various neurological diseases.